Vera V. Morozova
Russian Academy of Sciences
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Vera V. Morozova.
Human antibodies | 2010
M.A. Vikhrova; M.V. Shveygert; E.A. Khrapov; Maksim L. Filipenko; I.P. Gileva; Vera V. Morozova; Nina V. Tikunova
Four unique phage single-chain variable fragments (scFvs) to recombinant human interleukin 18 (IL-18) has been selected from a naïve combinatorial library of human scFvs. Binding of unique phage antibodies with IL-18 was tested by ELISA and Western-blotting. No cross reactivity with tumor necrosis factor α, interferons α and γ was shown for the selected antibodies. The gene segments encoding V(D)J regions of selected antibodies exhibited a high degree of homology to germline genes, therefore we suggest that the selected scFvs belong to repertoire of naïve autoantibodies.
Archive | 2018
Vera V. Morozova; Yulia N. Kozlova; Denis A. Ganichev; Nina V. Tikunova
Diabetic foot ulcers occur as a common complication of diabetes. Healing of the ulcers is largely delayed by the concomitant infection. Antibiotic treatment of infected ulcers is complicated by formation of microbial biofilms , which are often heterogeneous and resistant to antibiotics. Bacteriophage therapy is considered as an additional approach to the treatment of infected wounds. Here, we describe the basic method of application of bacteriophages for treatment of infected diabetic foot ulcers, including ones that are very large.
Virus Research | 2012
Nina V. Tikunova; Viktoriya Dubrovskaya; Vera V. Morozova; Tatiana Yun; Yana Khlusevich; Nikolai Bormotov; Aleksandr Laman; F. A. Brovko; Aleksandr Shvalov; Eugeni Belanov
A panel of recombinant human antibodies to orthopoxviruses was isolated from a combinatorial phage display library of human scFv antibodies constructed from the Vh and Vl genes cloned from the peripheral blood lymphocytes of Vaccinia virus (VACV) immune donors. Plaque-reduction neutralization tests showed that seven selected phage-displaying scFv antibodies (pdAbs) neutralized both CPXV and VACV, and five of them neutralized Monkeypox virus (MPXV). Western blot analysis of VACV and CPXV proteins demonstrated that seven neutralizing antibodies recognized a 35 kDa protein. To identify this target protein, we produced a recombinant J3L protein of CPXV and showed that all the selected neutralizing antibodies recognized this protein. Neutralizing pdAb b9 was converted into fully human mAb b9 (fh b9), and scFv b9 displayed high binding affinities (K(d) of 0.7 and 3.2 nM). The fh b9 reduced VACV plaque formation in a dose-dependent manner.
Immunological Investigations | 2015
Valentin A. Ustinov; Artem E. Studennikov; Vitaliy A. Vavilov; Marina A. Tyumentseva; Vera V. Morozova; Nina V. Tikunova; Andrey N. Glushkov
Polycyclic aromatic hydrocarbons (PAHs) are widely distributed and relocated in the environment as a result of the incomplete combustion of organic matter. Many PAHs and their epoxides are highly toxic, mutagenic and/or carcinogenic to microorganisms as well as to higher systems including humans. BP is one of the most toxicologically active PAHs and is often used as a prototype for this entire class of contaminants. In order to select anti-BP antibodies, the conjugate of BP with BSA (BP-BSA) was used to screen naïve combinatorial phage library of human scFvs. Seven unique scFvs against BP-BSA were selected after three rounds of selection. Analysis of the genes encoding the scFvs subdivided them to gene families and subfamilies. Homology with the closest germline ranged from 80.21% to 97.57% for heavy chains and 88.89% to 98.57% for the light chains. Four of the seven scFv amino acid residues sequences without stop codons in frame were selected for proteomic analysis with each other. Four scFvs encoded unique non-related proteins with low-sequence identity among them. All CDRs and the boundaries in the CDR3 formation were carried out. Two of the scFvs (T68 and T72) with the highest binding capabilities to PAHs were expressed in E. coli and purified using a nickel resin. The KDs of T68 to BP-BSA, chrysene, pyrene, and benzo[a]anthracene were almost similar, approximately 10−7 M. The KDs of T72 to benzo[a]anthracene and chrysene were 9.42 × 10−8 M and 2.63 × 10−7 M, respectively. The computational models of T68 and T72 active centers were different.
Solid State Phenomena | 2010
V. S. Rudnev; Alexander Yu. Ustinov; I. V. Lukiyanchuk; P. V. Kharitonskii; A. Frolov; Vera V. Morozova; I. A. Tkachenko; M.V. Adigamova
Magnetic properties of iron-containing coatings obtained on aluminum by plasma electrolytic oxidation were analyzed in this paper. Theoretical curves of demagnetization of these objects are obtained. It is shown that the magnetic states of the analyzed samples can be caused by the presence of several phases with very different magnetic properties.
Central European Journal of Immunology | 2017
Artem E. Studennikov; Valentin A. Ustinov; Vera V. Morozova; Nina V. Tikunova; Andrey N. Glushkov
The nal¨ve library from the lymphocytes of healthy humans was screened by murine single-stranded idiotypic antibodies against benzo[a]pyrene (pSh). The phage clone which contained of anti-idiotypic antibody against benzo[a]pyrene, designated as A4, was chosen for further work because of highly specific to pSh. The available protein databases were searched. The A4 amino acid sequence was unique and 76% identical to a sequence in antibody against interferon g. The A4 protein was expressed in bacteria and purified by two different methods: His-tagged A4 and CBD-fusion A4. Both the A4 bound to pSh and also to the human single chain idiotypic antibody against the benzo[a]pyrene (T72) by ELISA. The Kd values of A4 for pSh and T72 were very close: 4.44 × 10-7 M and 5.71 × 10-7M, respectively. A4 was a competitor with benzo[a]pyrene for binding sites of both idiotypic pSh and T72 in competitive ELISA. Thus, A4 was a high affinity anti-idiotypic against benzo[a]pyrene which recognised pSh and T72 active sites.
Immunogenetics | 2016
Marina Tiumentseva; Vera V. Morozova; Aleksandr I. Zakabunin; Denis Sergeevich Korobko; Nadezhda Malkova; Maksim L. Filipenko; Nina V. Tikunova
We investigated whether levels and repertoires of anti-interleukin-18 (IL-18) autoantibodies (auto-Abs) differ in multiple sclerosis (MS) patients and healthy donors (HDs). IL-18 concentration in MS patients’ sera was higher than in HD, but the level of anti-IL-18 auto-Abs was lower in MS patients. Correlation patterns of IL-18/anti-IL-18 auto-Abs system differed in HD and MS patients, so we have compared segment composition of the anti-IL-18 single-chain variable fragments (scFvs) selected from MS and naïve phage display libraries. Considerable differences between anti-IL-18 auto-Abs of these libraries were found. MS panel contained auto-Abs displaying both signs of “fetal” and somatically hypermutated repertoires. Naïve panel mainly contained the naïve antibodies. These variations from the norm are possible results of abnormal regulation of the repertoire perhaps determined by remodeling of the molecular mechanisms involved in the V(D)J recombination and/or abnormal selection by antigen in MS pathogenesis.
Frontiers in Microbiology | 2018
Vera V. Morozova; Valentin V. Vlassov; Nina V. Tikunova
In the recent years, multidrug-resistant bacteria have become a global threat, and phage therapy may to be used as an alternative to antibiotics or, at least, as a supplementary approach to treatment of some bacterial infections. Here, we describe the results of bacteriophage application in clinical practice for the treatment of localized infections in wounds, burns, and trophic ulcers, including diabetic foot ulcers. This mini-review includes data from various studies available in English, as well as serial case reports published in Russian scientific literature (with, at least, abstracts accessible in English). Since, it would be impossible to describe all historical Russian publications; we focused on publications included clear data on dosage and rout of phage administration.
Antiviral Research | 2018
Yana Khlusevich; Andrey L. Matveev; Ivan K. Baykov; Leonid Bulychev; Nikolai Bormotov; Ivan Ilyichev; Georgiy Yu. Shevelev; Vera V. Morozova; D. V. Pyshnyi; Nina V. Tikunova
ABSTRACT In this study, five phage display antibodies (pdAbs) against ectromelia virus (ECTV) were selected from vaccinia virus (VACV)‐immune phage‐display library of human single chain variable fragments (scFv). ELISA demonstrated that selected pdAbs could recognize ECTV, VACV, and cowpox virus (CPXV). Atomic force microscopy visualized binding of the pdAbs to VACV. Three of the selected pdAbs neutralized variola virus (VARV) in the plaque reduction neutralization test. Western blot analysis of ECTV, VARV, VACV, and CPXV proteins indicated that neutralizing pdAbs bound orthopoxvirus 35 kDa proteins, which are encoded by the open reading frames orthologous to the ORF H3L in VACV. The fully human antibody fh1A was constructed on the base of the VH and VL domains of pdAb, which demonstrated a dose‐dependent inhibition of plaque formation after infection with VARV, VACV, and CPXV. To determine the p35 region responsible for binding to neutralizing pdAbs, a panel of truncated p35 proteins was designed and expressed in Escherichia coli cells, and a minimal p35 fragment recognized by selected neutralizing pdAbs was identified. In addition, peptide phage‐display combinatorial libraries were applied to localize the epitope. The obtained data indicated that the epitope responsible for recognition by the neutralizing pdAbs is discontinuous and amino acid residues located within two p35 regions, 15–19 aa and 232–237 aa, are involved in binding with neutralizing anti‐p35 antibodies. HighlightsPhage display antibodies selected against ectromelia virus were able to neutralize variola virus.Neutralizing phage display antibodies recognized p35 (H3L) protein of orthopoxviruses.Neutralizing epitope was discontinuous and located within two p35 regions, 15–19 aa and 232–237 aa.A fully human antibody was constructed using VH‐ and VL‐domains of a phage display antibody neutralizing of variola virus.
Human antibodies | 2013
Marina A. Tyumentseva; Vera V. Morozova; Leonid R. Lebedev; Igor V. Babkin; Nina V. Tikunova
Collaboration
Dive into the Vera V. Morozova's collaboration.
State Research Center of Virology and Biotechnology VECTOR
View shared research outputs